 Connection
David Moreno to Drug Resistance, Neoplasm
This is a "connection" page, showing publications David Moreno has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.291 |
|
|
|
-
Moreno DF, Clap?s V, Soler JA, Gonz?lez-Montes Y, Gironella M, Motll? C, Granell M, Abella E, Garc?a-Pintos M, Garc?a-Gui??n A, Cabezudo E, Blad? J, Rosi?ol L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):635-642.
Score: 0.147
-
Oliver-Caldes A, Jim?nez R, Espa?ol-Rego M, Cibeira MT, Ortiz-Maldonado V, Quintana LF, Castillo P, Guijarro F, Tovar N, Montoro M, Benitez-Ribas D, Bataller A, Gonz?lez-Navarro EA, Cid J, Lozano M, Perez-Amill L, Martin-Antonio B, Mena MP, Moreno DF, Rodr?guez-Lobato LG, Campistol JM, Calvo G, Blad? J, Rosi?ol L, Juan M, Pascal M, Urbano-Ispizua A, Fern?ndez de Larrea C. First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma. J Immunother Cancer. 2021 12; 9(12).
Score: 0.143
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|